메뉴 건너뛰기




Volumn 8, Issue 1, 2012, Pages 109-116

Clinical performance of a drug-eluting stent with a biodegradable polymer in an unselected patient population: The NOBORI 2 study

(16)  Danzi, Gian Battista a   Chevalier, Bernard b   Urban, Philip c   Fath Ordoubadi, Farzin d   Carrie, Didier e   Wiemer, Marcus f   Serra, Antonio g,h   Wijns, William i   Kala, Petr j   Stabile, Amerigo k   Ruigomez, Javier Goicolea l   Sagic, Dragan m   Laanmets, Peep n   Strupp, Gerhard o   West, Nick p   Paunovic, Dragica q  


Author keywords

Biodegradable polymer; Drug eluting stent; Off label indication

Indexed keywords

DRUG CARRIER; POLYLACTIC ACID; UMIROLIMUS;

EID: 84864202983     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV8I1A17     Document Type: Article
Times cited : (43)

References (31)
  • 4
    • 33747613296 scopus 로고    scopus 로고
    • Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the ENDEAVOR II trial
    • Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114:798-806.
    • (2006) Circulation , vol.114 , pp. 798-806
    • Fajadet, J.1    Wijns, W.2    Laarman, G.J.3    Kuck, K.H.4    Ormiston, J.5    Munzel, T.6    Popma, J.J.7    Fitzgerald, P.J.8    Bonan, R.9    Kuntz, R.E.10
  • 19
    • 84867863485 scopus 로고    scopus 로고
    • Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries
    • Jul 29. doi: 10.1002/ccd.23280. [Epub ahead of print]
    • Kadota K, Muramatsu T, Iwabuchi M, Saito S, Hayashi Y, Ikari Y, et al. Randomized comparison of the Nobori biolimus A9-eluting stent with the sirolimus-eluting stent in patients with stenosis in native coronary arteries. Catheter Cardiovasc Interv. 2011 Jul 29. doi: 10.1002/ccd.23280. [Epub ahead of print]
    • (2011) Catheter Cardiovasc Interv
    • Kadota, K.1    Muramatsu, T.2    Iwabuchi, M.3    Saito, S.4    Hayashi, Y.5    Ikari, Y.6
  • 22
    • 0023092594 scopus 로고
    • A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation
    • Charlson ME, Pompei P, Ales KL, McKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373-83.
    • (1987) J Chron Dis , vol.40 , pp. 373-383
    • Charlson, M.E.1    Pompei, P.2    Ales, K.L.3    McKenzie, C.R.4
  • 27
    • 79959502100 scopus 로고    scopus 로고
    • 2-Year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: A randomized open label trial)
    • Smits PC, Kedhi E, Royaards KJ, Joesoef KS, Wassing J, Rademaker-Havinga TA, McFadden E.2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTÉ stent in all-comers: a randomized open label trial). J Am Coll Cardiol. 2011;58:11-8.
    • (2011) J Am Coll Cardiol , vol.58 , pp. 11-18
    • Smits, P.C.1    Kedhi, E.2    Royaards, K.J.3    Joesoef, K.S.4    Wassing, J.5    Rademaker-Havinga, T.A.6    McFadden, E.7
  • 29
    • 68749099627 scopus 로고    scopus 로고
    • In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: Results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry
    • Novack V, Cutlip D, Kleiman N, Pencina M, Mauri L, Yen CH, Berger P, Goldberg S, Kellett M, Waksman R, Hong M, Raizner AE, Cohen DJ. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv. 2009;2:767-775.
    • (2009) JACC Cardiovasc Interv , vol.2 , pp. 767-775
    • Novack, V.1    Cutlip, D.2    Kleiman, N.3    Pencina, M.4    Mauri, L.5    Yen, C.H.6    Berger, P.7    Goldberg, S.8    Kellett, M.9    Waksman, R.10    Hong, M.11    Raizner, A.E.12    Cohen, D.J.13
  • 30
    • 33645416316 scopus 로고    scopus 로고
    • Sirolimus-eluting stents remain superior to bare-metal stents at two years: Medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry
    • Ong AT, van Domburg RT, Aoki J, Sonnenschein K, Lemos PA, Serruys PW. Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 2006;47:1356-1360.
    • (2006) J Am Coll Cardiol , vol.47 , pp. 1356-1360
    • Ong, A.T.1    Van Domburg, R.T.2    Aoki, J.3    Sonnenschein, K.4    Lemos, P.A.5    Serruys, P.W.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.